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Abstract. The purposes of this study were: (1) to
determine under steady-state conditions whether the
renal clearance of prednisolone is concentration
dependent, and (2) to establish whether the urinary
excretion of prednisolone and its biologically inactive
11 -dehydro metabolite prednisone depend upon the
activity of 11 (3-hydroxysteroid dehydrogenase (11P-
OHSD). For that purpose 10 healthy volunteers were
infused to steady state over a 13-h period either at a
low (11 ug/h x kg) or a high (70 ug/h x kg) rate with
prednisolone on two occasions, once without and once
with administration of glycyrrhetinic acid, an inhibitor
of 11 P-OHSD. Prednisolone and prednisone were
measured by high-pressure liquid chromatography.
Mean renal clearance values of total or unbound
prednisolone were several times higher during the high
than the low infusion rate. The fractional renal clear-
ance of unbound prednisolone during the high, but
not during the low infusion rate exceeded 1. This
indicates that in addition to unbound prednisolone,
protein-bound prednisolone is excreted in urine at high
plasma concentrations. Inhibition of 11(3-OHSD
increased the urinary ratios of prednisolone/prednisone
in all subjects. Conclusions: (1) The renal clearance of
prednisolone is concentration dependent; (2) there
must be tubular secretion and/or glomerular filtration
of prednisolone bound to plasma proteins; (3) the
urinary excretion of prednisolone/prednisone is modu-
lated by the activity of 11 P-OHSD.
Key words: clearance; 11 P-hydroxy-steroid dehydro-
genase; glycyrrhetinic acid; humans; prednisolone;
prednisone
Introduction
For virtually all endo- or xenobiotics the total body
clearance value is concentration independent or
Correspondence and offprint requests to: Brigitte M. Frey, PhD,
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declines with increasing free concentrations as a con-
sequence of saturation of the elimination process [1].
This is also the case for agents excreted mainly by the
kidney, such as inulin, creatinine, para-aminohippurate
or others. Prednisolone, however exhibits a peculiar
kinetic feature: the total body clearance increases with
increasing plasma concentrations of the steroid (for
review see refs [2,3]). Part, but not all of the changes
in clearance are related to changes in the plasma
protein binding of prednisolone [4], In addition
increased excretion and/or metabolism of prednisolone
with increasing concentrations must also be postulated
as the second mechanism of the dose dependency. The
assessment of the latter is complicated by the intercon-
version process between prednisolone and prednisone
[2,3]. The organ(s) which might have the functional
capability to enhance the clearance with increasing
concentrations have not been identified. Therefore it
is of general interest to establish whether the kidney
could account for such an unusual concentration-
dependent clearance. One purpose of the present
investigation was thus to establish whether the renal
clearance of prednisolone increases with increasing free
prednisolone concentrations in plasma.
Cortisol is converted to its 11-dehydro metabolite,
cortisone by the microsomal enzyme 11 P-OHSD [5].
Recently differential tissue distribution of 11P-OHSD
has been observed [6]. The tissue-specific distribution
of 11 P-OHSD is thought to confer specificity to min-
eralocorticoids in the presence of glucocorticoids in
mineralocorticoid target tissues [7]. The activity of
11 P-OHSD can be modulated by endo- and xenobiotics
[7,8]. Among the xenobiotics liquorice extracts, derived
from roots of the plant Glycyrrhizia glabra, used for
decades as flavouring agents for food and beverages
are probably the most relevant. It was demonstrated
that glycyrrhetinic acid (GA), the hydrolytic product
of glycyrrhizic acid exhibits mineralocorticoid activity
by inhibiting the oxidation of the hydroxyl group at
11th position of cortisol [9]. Cortisol is structurally
related to prednisolone. It is assumed, that 11 P-OHSD
accounts also for the conversion of the immuno-
suppressive agent prednisolone to the biologically
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11 P-Hydroxysteroid dehydrogenase and prednisolone/prednisone
inactive metabolite prednisone [2,3]. Therefore in the
present investigation GA was administered during infu-
sions of prednisolone in order to assess the impact of
the inhibition of 11P-OHSD on the renal handling of
prednisolone/prednisone at steady state.
Subjects and Methods
Subjects
Ten male volunteers, ranging in age from 20 to 30 years and
weight from 55 to 75 kg, participated in the study. The
volunteers were not on chronic drug therapy. Two weeks
before the study was initiated no food intake containing
glycyrrhetinic acid derivatives were allowed. The subjects
gave informed consent according to a protocol approved by
the Ethics Committee at our institution.
Protocol
The volunteers were investigated on two occasions separated
by 7 days. All studies were started between 07.00 and 08.00.
Catheters were placed in veins of each arm to allow simultan-
eous glucocorticoid, glucose, NaCl, and KC1 infusion and
blood sampling. Prednisolone (Hydeltrasol®) was infused
over a 13-h period at a rate of 70 |a.g/kg/h following an i.v.
bolus dose of 450 ug/kg in five subjects and at a rate of
11 ug/kg/h following an i.v. bolus dose of 70 ug/kg in five
additional subjects. In a previous investigation we demon-
strated that by administering these doses a steady state of
prednisolone and prednisone is achieved within 3 h [4]. The
volume of solute infused continuously over the 13-h study
period was 2 1 containing a total of 66 g of glucose, 122 mmol
of sodium, 40 mmol of potassium, and 162 mmol of chloride.
No food and fluid intake was allowed during that period.
Six and 9 h after the beginning of the infusion two capsules
containing each 200 mg of GA or saccharose (placebo) were
given. On each study day 5 ml blood samples were collected
just before steroid administration and 15, 60, 120, 180, 270,
315, 360, 420, 510, 600, 690, and 780 min after i.v. predniso-
lone dosing. Three urine collections were obtained on each
study day (180-360 min, 420-600 min, 600-780 min).
Analytical methods
Plasma samples were analysed for prednisolone and prednis-
one by a previously described HPLC procedure [10]. The
intraday assay variability coefficient of variation (CV) of
this method is 1-4%, the interday assay CV 2.8-10.6% [10].
Equilibrium dialysis was performed to quantify the concen-
tration of unbound prednisolone in plasma as described [11].
Because of the concentration-dependent protein binding of
prednisolone, protein binding was determined in each plasma
sample from each subject. The intraday variability for the
protein binding measurements was found to be 1.2%, the
interday variability 1.6%. The in-vitro fraction of unbound
prednisolone was calculated by dividing the concentration in
the buffer half-cell by the concentration in the plasma half-
cell. Because prednisolone protein binding is non-linear it is
necessary to correct the binding parameters for the changes
in concentration that are caused by diffusion from plasma
into buffer during equilibrium dialysis. This was done by the
method of Behm and Wagner [12]. Prednisolone, prednisone
and 6p-hydroxyprednisolone were assessed in urine using a
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previously described HPLC procedure [13] exhibiting an
intraday CV of 5.5-10.9% and an interday CV of
4.5-11.6% [13].
Calculations
Renal clearance values of total and unbound prednisolone
and prednisone were calculated by dividing the amount of
prednisolone recovered in the urine by the corresponding
plasma concentrations of the steroid. An estimate of the
fractional renal clearance of the steroids was derived by
dividing the renal clearance of the steroid by the glomerular
filtration rate as assessed by the creatinine clearance. Non-
renal clearance (metabolic clearance) values were obtained
by subtracting renal clearance from total body clearance
values. Statistical analysis was performed with the help of
the Statistical Analysis System software package (version OS
6.03, SAS Institute Inc., Carry, NJ). Comparison for vari-
ations over time was performed by analysis of variance,
using the Hotelling-Lawley-Spur test, selecting the variation
over time with GA versus placebo. All the values are given
as mean ±SE.
Results
Six hours after the bolus injection followed by the
perfusion of prednisolone, prednisolone and prednis-
one concentrations in plasma were at steady state
(Table 1). These concentrations remained constant up
to 780 min when placebo was administered. The first
dose of 400 mg GA was given at 360 min, and the
second dose at 540 min (Table 1, Figure 1). From 510
min until the end of the experiment, the prednisone
concentrations in plasma steadily declined when GA,
but not placebo, was given (Table 1). During the same
time period, the concentrations of prednisolone
increased when low doses, but not when high doses,
of prednisolone were infused (Table 1). As a con-
sequence, following the administration of GA, the
prednisolone/prednisone concentration ratios in
plasma increased (Fig. 1, open symbols).
The first urine collection was performed before
(180-360 min), and two additional collections after
the administration of GA (420-600 min, 600-780 min)
(Table 2). Following the low infusion of prednisolone,
the rate of prednisolone excretion increased and that
of prednisone decreased after the administration of
GA. As a consequence, the urinary prednisolone/
prednisone concentration ratios increased after GA
(Figure 1, dark columns). Furthermore, a decline in
the urinary excretion rate of prednisone was seen after
the high infusion rate of prednisolone (Table 2).
Therefore, also the urinary prednisolone/prednisone
ratios increased after the high infusion of predniso-
lone when GA was given (Figure 1, dark columns,
600-780 min). The increase of the urinary ratio of
prednisolone/prednisone was present in all subjects
(P<0.05) and more pronounced after the low than
after the high dose of prednisolone (Figure 1).
At each time-point the mean prednisolone/prednis-
one concentration ratio (without GA) in plasma was
higher during the high than during the low infusion
1624 M. Conti et al.
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rate of prednisolone (P<0.001) (Figure 1, open sym-
bols). A similar dose dependency of the prednisolone/
prednisone ratio was found for urine (Figure 1, open
columns). The mean values of these ratios in urine
were more than three times higher during the high
than during the low infusion rate of prednisolone
(Figure 1, open columns). The maximum effect of GA
on the prednisolone/prednisone concentration ratios
was observed only after several hours, an observation
in line with the time to peak concentration of GA
following dosing of the inhibitor [14].
GA did not change the total body clearance of total
or unbound prednisolone (low dose, without versus
with GA: 1.4 + 0.1 versus 1.3+0.1 ml/min x kg; high
dose, without versus with GA: 3.4 + 0.1 versus
3.6±0.2 ml/min x kg). Similarly, GA did not influence
the total body clearance of prednisolone when calcu-
lated with reference to unbound steroid concentrations
(low dose, without versus with GA: 8.8±0.9 versus
8.2 ±0.5 ml/minx kg; high dose, without versus with
GA: 15.0 + 0.9 versus 15.7 +1.8 ml/minx kg). In all
subjects given the high infusion rate of prednisolone,
the clearance values were higher than those during the
low infusion rate. All the aforementioned clearance
values were calculated by considering the time period
between 600 and 780 min. Similar results were obtained
when the earlier time periods (180-360 min or
420-600 min, Figure 1) were analysed.
The renal clearance of prednisolone and prednisone
increased with increasing steroid dose (Figure 2,
Table 3). This concentration dependency was not due
to an altered glomerular filtration rate because the
corresponding fractional renal clearance values fol-
lowed the same dose dependency. The values of the
fractional renal clearance of prednisolone following
the high dose of prednisolone were higher than one
in all subjects (Table 3). The renal clearance values
of prednisolone obtained from the low-dose study
increased after the administration of GA (Figure 2).
Discussion
Prednisolone exhibits concentration-dependent kinet-
ics, i.e. an increase in concentration results in an
increase in plasma clearance of prednisolone, as shown
in the present investigation [3,4]. Legler et al. presented
evidence that the changes in clearance are mostly
related to changes in the plasma protein binding of
prednisolone [4]. Prednisolone binds to transcortin
and albumin in a non-linear manner, with the percent-
age of unbound drug increasing with increasing steroid
concentration [3]. The relevance of protein binding for
the dose-dependency of prednisolone kinetics is sup-
ported by the observation that subjects exhibiting an
abnormally high binding of prednisolone to plasma
proteins (women taking oestrogen-containing oral
contraceptive steroids) have decreased values of total
body clearance when calculated with reference to total
prednisolone concentrations, whereas individuals
exhibiting an abnormally low binding of prednisolone
11 p-Hydroxysteroid dehydrogenase and prednisolone/prednisone
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Fig. 1. Prednisolone/prednisone concentration ratios in plasma and urine following a low (left) and a high (right) infusion rate of
prednisolone. The arrows indicate the intake of glycyrrhetinic acid or placebo. The open circles and columns represent results obtained
following placebo and the closed circles and columns those following glycyrrhetinic acid. Prednisolone/prednisone ratios were higher
following the high than the low infusion rate, both in plasma and in urine. The plasma ratios increased in all subjects (P<0.05) after 510
min and 600 min following the low and the high infusion rate respectively. The urinary ratios increased after glycyrrhetinic acid in all
subjects investigated.
Table 2. Prednisolone and prednisone in urine after low or high
infusion rates of prednisolone with or without glycyrrhetinic acid
Min 180-360* 420-600* 600-780*
Prednisolone low dose + glycyrrhetinic acid
Prednisolone ug/3 h 195 ±29 286 ±42 376 + 46
Prednisone ug/3 h 131 ±25 106+16 71 ±9
Prednisolone low dose + placebo
Prednisolone ug/3 h 248±53 190 + 50 158±32
Prednisone ug/3 h 165±11 111+22 100± 15
Prednisolone high dose + glycyrrhetinic acid
Prednisolone ug/3 h 3241 ±312 2503 ±89 2953 ±340
Prednisone u.g/3 h 545 ±33 405 + 49 306 ±69
Prednisolone high dose + placebo
Prednisolone ug/3 h 2619 + 392 2561 ±346 2737±310
Prednisone ug/3 h 434±30 458 + 59 389±31
* Before glycyrrhetinic acid; ** after glycyrrhetinic acid.
to plasma proteins (nephrotic patients) have increased
values of these parameters [15-18].
In addition to the concentration-dependent plasma
protein binding, the concentration-dependent total
body clearance of unbound prednisolone also accounts
for part of the concentration-dependent clearance of
total prednisolone as shown by Legler et al. [4], The
present study reveals that part of the concentration-
dependent total body clearance of unbound steroids
is due to a rise in renal clearance with increasing
concentrations of prednisolone (Figure 2). The dose-
dependent renal clearance cannot be explained by a
dose-dependent impact of the corticosteroid on the
glomerular filtration rate, because the ratios of renal
clearance of total or unbound prednisolone to the
creatinine clearance (fractional renal clearance) were
higher after the high than after the low dose of
the steroid.
The observed renal clearance values of prednisolone
are not consistent with the involvement of glomerular
filtration of unbound prednisolone alone. In addition
to glomerular filtration of unbound prednisolone there
must be filtration and/or active tubular secretion of
prednisolone bound to plasma proteins. Compared to
transcortin, albumin exhibits 104 times lower affinity
for prednisolone binding [18]. Thus prednisolone
bound to albumin rather than prednisolone bound to
transcortin may be filtered or secreted. At low concen-
trations most prednisolone is bound to transcortin.
With increasing concentrations a larger fraction is
bound to albumin, thus increasing the availability for
excretion of prednisolone with increasing plasma
concentrations.
An alternative explanation for the increase of the
prednisolone clearance with increasing concentrations
of prednisolone might be a saturation of the 11(3-
OHSD at high prednisolone concentrations. In line
with that hypothesis is the observation that during the
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Fig. 2. Renal clearance and fractional renal clearance of unbound prednisolone before and after glycyrrhetinic acid (GA) during low or
high infusion rates of prednisolone. Both clearance values were higher in all subjects when calculated during the high than during the low
infusion rate of prednisolone. Glycyrrhetinic acid increased these values in eight, of 10 subjects.
Table 3. Renal clearance of prednisolone and prednisone following high and low infusion rates of prednisolone without and with
glycyrrhetinic acid
Measurements
Renal clearance (ml/min x kg):
Total prednisolone
Unbound prednisolone
Prednisone
Creatinine clearance
(ml/min x kg)
Fractional renal clearance:
Total prednisolone
Unbound prednisolone
Prednisone
Plus-minus values are means+ SE;
Without glycyrrhetinic acid
High dose
0.65 + 0.03
2.87 + 0.15
0.80 + 0.06
1.8 + 0.1
0.37 + 0.02
1.61 ±0.09
0.45 ±0.04
Low dose
0.10 + 0.02"
0.58 + 0.05"
0.33 ±0.05
1.6±0.1
0.06 + 0.01c
0.35 + 0.04"
0.20 + 0.04
a, /><0.02; b, P<0.01; c, P<0.02; d,
P values
<0.05
<0.05
<0.05
n.s.
<0.05
<0.05
<0.05
P<0.001.
With glycyrrhetinic acid
High dose
0.82 + 0.10
3.45 + 0.38
0.96 ±0.26
1.9 + 0.1
0.42 ±0.05
1.75 + 0.17
0.49 + 0.13
Low dose
0.21+0.02"
1.30 + 0.12"
0.49 ±0.04
1.6 + 0.2
0.14 + 0.02°
0.76 + 0.04"
0.30 + 0.03
P values
<0.05
<0.05
n.s.
n.s.
<0.05
<0.05
n.s.
low infusion rate of prednisolone, the renal clearance
increased in all subjects after the administration of GA
(Figure 2). A similar increase was observed in three of
five subjects during the high infusion with prednisolone
(Figure 2). The explanation of the saturation of llp-
OHSD at high concentrations of prednisolone, how-
ever, cannot explain completely the dose dependent
clearance of prednisolone for two reasons. First, the
inhibition of Ilf3-OHSD by GA did not increase the
renal clearance of prednisolone up to the level of high
dose without GA (Figure 2). Second, if the inhibition
of the conversion of prednisolone to prednisone was
relevant for the prednsiolone clearance, one might
predict a decline of the renal clearance of prednisone
after the administration of GA, which was not the case
(Table 3).
In the past, kinetics of prednisolone have usually
been assessed by administering a single oral dose of
prednisone or an i.v. bolus dose of prednisolone; thus,
the concentration measurements were not made at
steady state. In some of these studies the urinary
excretion of prednisolone was measured. These meas-
urements allowed a rough estimate of the renal hand-
ling of prednisolone. Interestingly, the fractional renal
clearance of unbound prednisolone after an i.v. bolus
dose of 0.8 mg/kg of prednisolone was reduced in
patients with nephrotic syndrome [17], subjects older
than 65 years [19] or in renal transplant patients
[20,21] when compared with normal healthy volun-
teers. The mean values of the fractional renal clearance
of unbound prednisolone were about 2.25 in healthy
volunteers, 1.25 in nephrotic patients, 0.98 in elderly
subjects, 0.75 in renal transplant patients 1 year after
transplantation with a steady decline to a value of 0.5
over the next 3-5 years following successful kidney
transplantation.
In the two groups of patients and in the elderly
subjects the creatinine clearance was slightly reduced
11 p-Hydroxysteroid dehydrogenase and prednisolone/prednisone
(mean value around 65 ml/min). This indicates that
patients with impaired renal function for various
reasons excrete relatively less prednisolone in urine. It
is conceivable that the transport system for predniso-
lone is impaired and/or the conversion of prednisolone
into prednisone by 11P-OHSD enhanced. The slightly
decreased urinary concentration ratios of prednisolone/
prednisone, observed in elderly subjects, nephrotics,
and renal transplant patients, are compatible with the
latter view. Evidence for a decrease of 11 P-OHSD
activity in patients with impaired renal function has
previously already been shown by Whitworth et al. by
determining cortisol/cortisone ratios in plasma from
patients with renal diseases [22].
The observation of increased urinary prednisolone,
despite there being no change in plasma levels, has
previously been found for cortisol following GA [23].
The apparent contradiction of an unchanged total
body clearance in the presence of an increased renal
clearance following GA is best explained by the obser-
vation that GA inhibits other enzymes involved in the
catabolism of corticosteroids [24]. Nevertheless the
absence of an effect of GA on the total body clearance
of prednisolone is partly at variance with a study of
Chen et al. [25]. These investigators found also no
impact of glycyrrhizin on the total prednisolone con-
centrations in plasma; however, they reported slightly
higher concentrations of unbound prednisolone. Chen
et al. measured only significantly higher unbound
prednisolone concentrations with than without gly-
cyrrhizin between the 4th and the 8th hour after
prednisolone dosing, but not during the initial 4 h.
Thus it is conceivable that at very low prednisolone
concentrations glycyrrhizin reduces the total body
clearance of prednisolone. Alternatively the difference
between the results of Chen et al. and those from the
present investigation may be explained by differences
in study design. Chen et al. administered a very low
dose of prednisolone (about 5 mg), injected glycyrrhi-
zin intravenously, and used a method for measuring
the free fraction of prednisolone that did not consider
the non-linear binding of prednisolone to plasma pro-
teins. Whether glycyrrhizin affected the interconversion
of prednisolone to prednisone or the renal clearance
of prednisolone is unknown, because the method did
not allow assessment specifically of prednisone and
prednisolone, and no urinary measurements were per-
formed [25].
GA modulates the activity of 11 P-OHSD. Inhibition
of that enzyme might account for local changes of the
concentration ratio between biological active predniso-
lone and inactive prednisone and by that mechanism
modulate mineralocorticoid and glucocorticoid effects.
We have recently shown that the prednisolone/prednis-
one concentration ratio was about 40 times higher in
liver than in kidney tissue and 5- to 15-fold higher in
lung, heart, spleen, or plasma than in kidney from rats
[26]. Inhibition of 11 P-OHSD by GA increased the
prednisolone/prednisone ratio in kidney and other
tissues [26]. This indicates that the increase of predni-
solone/prednisone in urine and plasma following GA
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observed in humans in the present study reflect corres-
ponding changes in tissues.
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